Quantitation of T-cell receptor frequencies by competitive PCR: Generation and evaluation of novel TCR subfamily and clone specific competitors

被引:13
作者
McKee, MD [1 ]
Clay, TM [1 ]
Rosenberg, SA [1 ]
Nishimura, MI [1 ]
机构
[1] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA
来源
JOURNAL OF IMMUNOTHERAPY | 1999年 / 22卷 / 02期
关键词
CTL clone; tumor infiltrating lymphocytes; competitive PCR; T cell receptor;
D O I
10.1097/00002371-199903000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
T cell receptor (TCR) V gene usage has been used to characterize the immune response to bacteria, viruses, allografts, self antigens, tumor antigens, and superantigens. Sensitive methods to detect changes in the frequency of TCR subfamilies or clonotypes might be useful in evaluating the efficacy of vaccines against infectious agents, immunotherapy treatments for cancer patients, or the status of autoimmune diseases. Two HLA-A2 restricted CTL clones expressing BV17 were isolated from a tumor infiltrating lymphocytes (TIL) culture of a patient with metastatic melanoma. One clone recognized the MART-1((27-35)) peptide and the other clone recognized the gp100((209-217)) peptide. The frequency of each of these CTL clones in an expanding TIL culture was measured using a novel competitive RT-PCR (cRT-PCR) strategy. cRT-PCR uses a single primer pair to amplify template cDNA simultaneously with a modified DNA competitor molecule. A rapid two-step PCR technique followed by a single cloning step was used to generate a TCR BV17 subfamily specific competitor or competitors specific for the MART-1((27-35)) reactive CTL clone (CO-41) and the gp100((209-217)) reactive CTL clone (CO-4). Each competitor contained a segment of the TCR BC region that served as an internal reference standard. Using the BV17 competitor we were able to accurately and reproducibly measure cDNA templates at a frequency as low as 1/100,000 using cDNA samples of known TCRBV subfamily composition. This competitor was used to monitor the frequency of BV17 expressing T cells in the TTL and PMBC of a patient with metastatic melanoma. We determined that the frequency of BV17 expressing T cells increased from 4.5% of the culture on day 35 to 60.7% of the culture on day 58. Expansion of the BV17 subfamily was due predominantly to the expansion of the CO-4 clone. This method can be used to meaningfully quantify the precursor frequency of T cell mRNA in prepared samples via TCR subfamily or TCR sequence specific primers.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 51 条
  • [1] Arden Bernhard, 1995, Immunogenetics, V42, P455
  • [2] ADOPTIVE IMMUNOTHERAPY OF ADVANCED MELANOMA PATIENTS WITH INTERLEUKIN-2 (IL-2) AND TUMOR-INFILTRATING LYMPHOCYTES SELECTED INVITRO WITH LOW-DOSES OF IL-2
    ARIENTI, F
    BELLI, F
    RIVOLTINI, L
    GAMBACORTIPASSERINI, C
    FURLAN, L
    MASCHERONI, L
    PRADA, A
    RIZZI, M
    MARCHESI, E
    VAGLINI, M
    PARMIANI, G
    CASCINELLI, N
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (05) : 315 - 322
  • [3] BARTH RJ, 1990, J IMMUNOL, V144, P1531
  • [4] Tumor antigens recognized by T cells
    Boon, T
    Coulie, PG
    VandenEynde, B
    [J]. IMMUNOLOGY TODAY, 1997, 18 (06): : 267 - 268
  • [5] DOUBLE-DIFFERENTIAL PCR FOR GENE DOSAGE ESTIMATION OF ERBB ONCOGENES IN BENIGN AND CANCER TISSUES AND COMPARISON TO CELLULAR DNA CONTENT
    BRANDT, B
    VOGT, U
    HARMS, F
    BOSSE, U
    ZANKER, KS
    ASSMANN, G
    [J]. GENE, 1995, 159 (01) : 29 - 34
  • [6] A RAPID AND VERSATILE METHOD TO SYNTHESIZE INTERNAL STANDARDS FOR COMPETITIVE PCR
    CELI, FS
    ZENILMAN, ME
    SHULDINER, AR
    [J]. NUCLEIC ACIDS RESEARCH, 1993, 21 (04) : 1047 - 1047
  • [7] CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
  • [8] Cormier JN, 1997, CANCER J, V3, P37
  • [9] DAILEY MO, 1982, P NATL ACAD SCI USA, V79, P5378
  • [10] DEKANT E, 1994, BIOTECHNIQUES, V17, P934